Biocatalytic C6 Building Block Synthesis via 2,3-Dehydroadipate Methyl Ester
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing adipic acid, caprolactam, 6-aminohexanoic acid, hexamethylenediamine, and 1,6-hexanediol rely heavily on petrochemical feedstocks and lack efficient biocatalytic pathways, as wild-type microorganisms do not naturally overproduce these C6 building blocks, contradicting the optimality principle for carbon flux.
Innovation Solution
Construction of biochemical pathways using 2,3-dehydroadipyl-CoA methyl ester to produce six-carbon aliphatic backbones with terminal functional groups, employing enzymes like fatty acid O-methyltransferase, trans-enoyl-CoA reductase, and pimelyl-[acp] methyl ester esterase, and cultivating recombinant hosts under specific conditions to optimize production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type microorganisms are used for producing C6 building blocks, then natural metabolism is maintained, but production efficiency is insufficient because no wild-type prokaryote or eukaryote naturally overproduces or excretes C6 Building Blocks
Solution Approach 1:
The patent divides the C6 building block production into separate functional modules: a carbon fixation pathway (Calvin cycle) for producing 2,3-dehydroadipyl-CoA, and a functional group addition pathway using engineered enzymes (fatty acid O-methyltransferase, trans-enoyl-CoA reductase, pimelyl-[acp] methyl ester esterase). This segmentation allows each pathway to be optimized independently, achieving high productivity while maintaining adaptability through modular enzyme selection.
Solution Approach 2:
The patent introduces 2,3-dehydroadipyl-CoA as a key intermediary compound that bridges carbon fixation and C6 building block synthesis. This intermediary enables the connection between simple carbon sources (CO2, acetate) and complex C6 products with terminal functional groups, resolving the contradiction by providing a controlled metabolic bridge that enhances productivity without requiring complete redesign of natural metabolism.
2Ease of manufacture
If petrochemical feedstocks are used for producing C6 building blocks, then established industrial processes are utilized, but sustainability is reduced due to reliance on non-renewable resources
Solution Approach 1:
The patent changes the fundamental parameter of carbon source from petrochemical-derived compounds to renewable biological sources (CO2, acetate, other C1-C6 compounds). This parameter change maintains ease of manufacture by using simple, readily available substrates while dramatically improving sustainability. The engineered pathways accept diverse carbon sources, making the process adaptable to different renewable feedstocks.
Solution Approach 2:
The patent replaces petrochemical synthesis mechanisms with biological catalysis. Instead of using high-energy chemical reactions and harsh conditions typical of petrochemical processing, the system employs enzyme-catalyzed transformations that operate under mild conditions. This substitution maintains manufacturing efficiency while eliminating the environmental harms associated with fossil fuel extraction and processing.
3Productivity
If carbon flux is directed towards C6 building blocks in wild-type microorganisms, then product formation is enhanced, but microbial growth optimality is compromised because no wild-type microorganism naturally overproduces C6 Building Blocks
Solution Approach 1:
The patent implements dynamic control of carbon flux through engineered regulatory mechanisms. The system can switch between growth-mode and production-mode by controlling enzyme expression levels and substrate availability. During growth phase, carbon flux supports biomass accumulation; during production phase, flux is redirected toward C6 building blocks. This dynamic adaptability resolves the contradiction by allowing the system to optimize for different objectives at different times.
Solution Approach 2:
The patent applies partial action by introducing only the specific enzymatic activities needed for C6 building block synthesis (fatty acid O-methyltransferase, trans-enoyl-CoA reductase, pimelyl-[acp] methyl ester esterase) rather than redesigning entire metabolic pathways. This partial engineering approach enhances productivity for target products while preserving the core metabolic functions that maintain microbial growth optimality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient, biocatalytic production of C6 building blocks, overcoming the limitations of natural pathways and petrochemical dependence, by directing carbon flux towards desired products while maintaining microbial growth optimality.
Implementation Method 1
a polypeptide having the activity of a fatty acid O-methyltransferase
Implementation Method 2
enzymatically converting a n-carboxy-2-enoic acid to a n-carboxy-2-enoate methyl ester using a polypeptide having the activity of a fatty acid O-methyltransferase
Implementation Method 3
a polypeptide having trans-enoyl-CoA reductase activity
Implementation Method 4
enzymatically converting 2,3-dehydroadipyl-CoA methyl ester to adipyl-CoA using a polypeptide having trans-enoyl-CoA reductase activity
Implementation Method 5
a polypeptide having pimelyl-[acp] methyl ester esterase activity
Implementation Method 6
enzymatically converting adipyl-CoA methyl ester to adipyl-CoA using a polypeptide having pimelyl-[acp] methyl ester esterase activity
Implementation Method 7
biotechnology offers an alternative approach via biocatalysis. Biocatalysis is the use of biological catalysts, such as enzymes, to perform biochemical transformations of organic compounds
Implementation Method 8
Any of the methods can be performed in a recombinant host by fermentation
Data Source
AI summary
This document describes biochemical pathways for producing 2,3-dehydroadipyl-CoA methyl ester from precursors such as 2-oxoglutarate using one or more of a fatty acid O-methyltransferase, a thioesterase, a CoA-transferase and a CoA ligase, as well as recombinant hosts expressing one or more of such enzymes. 2,3-dehydroadipyl-CoA methyl ester can be enzymatically converted to adipyl-CoA using a trans-2-enoyl-CoA reductase, and a methylesterase, which in turn can be enzymatically converted to adipic acid, 6-aminohexanoate, 6-hydroxyhexanoate, caprolactam, hexamethylenediamine, or 1,6-hexanediol.